ISRCTN ISRCTN73232918
DOI https://doi.org/10.1186/ISRCTN73232918
Secondary identifying numbers NTR133
Submission date
20/12/2005
Registration date
20/12/2005
Last edited
18/03/2010
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Not provided at time of registration

Study website

Contact information

Dr D. van Schaardenburg
Scientific

Jan van Breemen Instituut
Dr. Jan van Breemenstraat 2
Amsterdam
1056 AB
Netherlands

Phone +31 (0)20 5896589
Email d.v.schaardenburg@janvanbreemen.nl

Study information

Study designRandomised, double blinded, placebo controlled, parallel group trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Not specified
Study typeTreatment
Scientific title
Study objectives1 - 2 intramuscular injections with 100 mg dexamethasone in persons without arthritis but with elevated serum levels of Rheumatoid Factor (RF) and or anti-Cyclic Citrullinated Peptide (aCCP) will lead to a reduction in antibody concentrations after 6 months and possibly to a lower frequency of rheumatoid arthritis after 5 years, in comparison to no treatment.
Ethics approval(s)Ethics approval received from the local medical ethics committee
Health condition(s) or problem(s) studiedRheumatoid arthritis
Intervention1 - 2 intramuscular injections with 100 mg dexamethason with 6 weeks interval (2nd injection with verum depends on response to first injection) or twice placebo.
Intervention typeDrug
Pharmaceutical study type(s)
PhaseNot Specified
Drug / device / biological / vaccine name(s)Dexamethasone
Primary outcome measure50% reduction of the concentration of the increased antibodies after 6 months compared to no treatment.
Secondary outcome measuresFrequency of rheumatoid arthritis after 5 years compared to no treatment.
Overall study start date01/10/2005
Completion date01/04/2008

Eligibility

Participant type(s)Patient
Age groupAdult
Lower age limit18 Years
SexBoth
Target number of participants80
Key inclusion criteria1. Age 18 - 70 years for RF+, 18+ for aCCP
2. Twice increased Immunoglobulin M (IgM)-RF and/or aCCP with 4+ weeks interval
3. Human Leukocyte Antigen (HLA)-DR Shared Epitope (SE) positive
Key exclusion criteriaSituations with possible false positive RF:
1. Auto-immune diseases
2. Active infection with hepatitis C or Ebstein Barr virus
3. Recent chemotherapy
4. Co-morbidity with decreased life expectancy
5. Corticosteroid use for another disease
6. Contra-indications for corticosteroids: diabetes mellitus, osteoporosis
7. Pregnancy or lactation
Date of first enrolment01/10/2005
Date of final enrolment01/04/2008

Locations

Countries of recruitment

  • Netherlands

Study participating centre

Jan van Breemen Instituut
Amsterdam
1056 AB
Netherlands

Sponsor information

Jan van Breemen Instituut (Netherlands)
Research organisation

Dr. Jan van Breemenstraat 2
Amsterdam
1056 AB
Netherlands

Website http://www.janvanbreemen.nl
ROR logo "ROR" https://ror.org/00bp9f906

Funders

Funder type

Research organisation

The Netherlands Organization for Health Research and Development (ZonMw) (Netherlands)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/03/2010 Yes No